SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain. This program, which is the Company’s second in the pain area, is advancing towards IND-enabling studies based on preclinical data presented in a poster at Neuroscience 2009, the 39th annual meeting of the Society for Neuroscience, taking place in Chicago, IL from October 17-21. KAI’s most-advanced pain program is focused on KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of epsilon PKC, which is currently enrolling patients in multiple phase 2a clinical studies.
